The prevalence, clinical features and association of HLA-B27 in sacroiliitis associated with established Crohn???s disease, Alimentary Pharmacology & Therapeutics, vol.5, issue.2 ,
DOI : 10.1097/00054725-199905000-00004
Inflammatory bowel disease associated arthropathy, Current Reviews in Musculoskeletal Medicine, vol.68, issue.18, pp.123-154, 2011. ,
DOI : 10.1136/ard.2008.092833
Prevalence of Self-Reported Spondyloarthritis Features in a Cohort of Patients with Inflammatory Bowel Disease, Canadian Journal of Gastroenterology, vol.27, issue.4, pp.199-205, 2013. ,
DOI : 10.1155/2013/139702
Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis, Rheumatology International, vol.59, issue.6, pp.357-360, 2012. ,
DOI : 10.1002/art.23704
Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors, Internal Medicine Journal, vol.76, issue.Suppl, pp.1154-1160, 2015. ,
DOI : 10.1016/j.jbspin.2008.12.008
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn???s Disease 2016: Part 1: Diagnosis and Medical Management, Journal of Crohn's and Colitis, vol.11, issue.1, pp.3-25, 2017. ,
DOI : 10.1093/ecco-jcc/jjw168
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders, Journal of Crohn's and Colitis, vol.124, issue.76, pp.649-670, 2017. ,
DOI : 10.1016/S0016-5085(03)00171-9
Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort, Annals of the Rheumatic Diseases, vol.43, issue.6, pp.1186-1195, 2014. ,
DOI : 10.1093/rheumatology/keh008
Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process, The American Journal of Gastroenterology, vol.12, issue.1, pp.1770-1776, 2012. ,
DOI : 10.1053/j.gastro.2005.12.019
Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis, Annals of the Rheumatic Diseases, vol.60, issue.7, pp.1357-1362, 2016. ,
DOI : 10.1002/art.24349
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target, The American Journal of Gastroenterology, vol.107, issue.9, pp.1324-1362, 2015. ,
DOI : 10.1038/ajg.2012.117
URL : https://hal.archives-ouvertes.fr/hal-01191653
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease, Gastroenterology, vol.138, issue.2, pp.463-471, 2010. ,
DOI : 10.1053/j.gastro.2009.09.056
Adalimumab Induces Deep Remission in Patients With Crohn's Disease, Clinical Gastroenterology and Hepatology, vol.12, issue.3, pp.414-436, 2014. ,
DOI : 10.1016/j.cgh.2013.06.019
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis, Gastroenterology, vol.141, issue.4, pp.1194-1201, 2011. ,
DOI : 10.1053/j.gastro.2011.06.054
Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experience, Alimentary Pharmacology & Therapeutics, vol.120, issue.1, pp.998-1004, 2013. ,
DOI : 10.1053/gast.2001.20912
URL : https://hal.archives-ouvertes.fr/hal-01703099
Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients, Journal of Crohn's and Colitis, vol.317, issue.12, pp.609-614, 2013. ,
DOI : 10.1056/NEJM198712243172603
Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.9, issue.6, pp.483-489, 2011. ,
DOI : 10.1016/j.cgh.2010.12.028
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis, Alimentary Pharmacology & Therapeutics, vol.14, issue.Suppl. 3, pp.1058-1072, 2017. ,
DOI : 10.1136/gutjnl-2016-312648
Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus, Alimentary Pharmacology & Therapeutics, vol.12, issue.6, pp.801-813, 2017. ,
DOI : 10.1016/j.cgh.2013.07.022
IOIBD technical review on endoscopic indices for Crohn's disease clinical trials, Gut, vol.59, issue.(Suppl), pp.1447-55, 2016. ,
DOI : 10.1136/gut.2009.194159
Superior Endoscopic and Deep Remission Outcomes in Adults with Moderate to Severe Crohn's Disease Managed with Treat to Target Approach Versus Clinical Symptoms: Data from Calm, Gastroenterology, vol.152, issue.5, p.155, 2017. ,
DOI : 10.1016/S0016-5085(17)30842-9
Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.12, issue.11, pp.1887-1893, 2014. ,
DOI : 10.1016/j.cgh.2014.03.035
A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry, Annals of the Rheumatic Diseases, vol.71, issue.6, pp.845-50, 2012. ,
DOI : 10.1136/annrheumdis-2011-200274
Treating to a Target in Established Active Rheumatoid Arthritis Patients Receiving a Tumor Necrosis Factor Inhibitor: Results From a Real-World Cluster-Randomized Adalimumab Trial, Arthritis Care & Research, vol.63, issue.9, pp.1401-1410, 2013. ,
DOI : 10.1002/acr.20643
Treat-to-Target in Spondyloarthritis: Implications for Clinical Trial Designs, Drugs, vol.74, issue.10, pp.1091-1097, 2014. ,
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis, Annals of the Rheumatic Diseases, vol.68, issue.(4), pp.978-991, 2017. ,
DOI : 10.1136/annrheumdis-2016-210770
High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort, Annals of the Rheumatic Diseases, vol.67, issue.10, pp.2114-2118, 2016. ,
DOI : 10.1002/art.23260
Anti-TNF-?? therapy with infliximab in spondyloarthritides, Expert Review of Clinical Immunology, vol.62, issue.1, pp.9-19, 2010. ,
DOI : 10.1136/ard.2003.009589
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force, Annals of the Rheumatic Diseases, vol.66, issue.suppl 2, pp.6-16, 2014. ,
DOI : 10.1136/ard.2007.071092
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, New England Journal of Medicine, vol.373, issue.26, pp.2534-2548, 2015. ,
DOI : 10.1056/NEJMoa1505066
Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis, The American Journal of Gastroenterology, vol.86, issue.4, pp.617-646, 2011. ,
DOI : 10.1056/NEJMoa0904492
Aminosalicylates for induction of remission or response in Crohn's disease, Cochrane Database Syst Rev, vol.7, p.8870, 2016. ,
Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis, The American Journal of Gastroenterology, vol.93, issue.4, pp.601-616, 2011. ,
DOI : 10.1016/0016-5085(87)90253-8
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis, Cochrane Database of Systematic Reviews, vol.3, issue.2, p.543, 2016. ,
DOI : 10.1002/14651858.CD000543.pub2
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis, Cochrane Database of Systematic Reviews, vol.3, issue.2, p.544, 2016. ,
DOI : 10.1002/14651858.CD000544.pub2
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management, Journal of Crohn's and Colitis, vol.111, issue.7, pp.1-24 ,
DOI : 10.1038/ajg.2016.54
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial, Annals of the Rheumatic Diseases, vol.65, issue.9, pp.1147-53, 2006. ,
DOI : 10.1136/ard.2006.052878
Sulfasalazine for ankylosing spondylitis, Cochrane Database Syst Rev, vol.11, p.4800, 2014. ,
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network, 2015. ,
Spondylitis Association of America/Spondyloarthrithis Research and treatment network recommendations for the treatment of r-axSpA and nr-axSpA ,
2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations, J Rheumatol, vol.4242, pp.665-681, 2015. ,
National Cooperative Crohn's Disease Study: results of drug treatment, Gastroenterology, vol.77, pp.847-69, 1979. ,
European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment, Gastroenterology, vol.86, pp.249-66, 1984. ,
Budesonide Foam Induces Remission in Downloaded by, p.36, 2017. ,
Response to Corticosteroids in Severe Ulcerative Colitis: A Systematic Review of the Literature and a Meta-Regression, Clinical Gastroenterology and Hepatology, vol.5, issue.1, pp.103-113, 2007. ,
DOI : 10.1016/j.cgh.2006.09.033
Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial, Annals of the Rheumatic Diseases, vol.70, issue.Suppl 2 ,
DOI : 10.1136/ard.2011.151043
New evidence on the management of spondyloarthritis, Nature Reviews Rheumatology, vol.74, issue.5, pp.282-95, 2016. ,
DOI : 10.1136/annrheumdis-2015-eular.2254
Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease, Cochrane Database Syst Rev, vol.10, p.545, 2016. ,
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis, Gut, vol.55, issue.1, pp.47-53, 2006. ,
DOI : 10.1136/gut.2005.068809
Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis???, Inflammatory Bowel Diseases, vol.15, issue.4, pp.613-622, 2010. ,
DOI : 10.1002/ibd.20875
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease, Cochrane Database of Systematic Reviews, vol.122, issue.1, p.67, 2015. ,
DOI : 10.1002/14651858.CD000067.pub2
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev Downloaded by, p.36, 2017. ,
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-95, 2010. ,
DOI : 10.1056/NEJMoa0904492
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis, Gastroenterology, vol.146, issue.2, pp.392-400, 2014. ,
DOI : 10.1053/j.gastro.2013.10.052
Methotrexate for the Treatment of Crohn's Disease, New England Journal of Medicine, vol.332, issue.5, pp.292-299, 1995. ,
DOI : 10.1056/NEJM199502023320503
Methotrexate for induction of remission in refractory Crohn's disease, Cochrane Database Syst Rev, vol.8, p.3459, 2014. ,
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease, Gastroenterology, vol.146, issue.3, pp.681-688, 2014. ,
DOI : 10.1053/j.gastro.2013.11.024
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative??Colitis, Gastroenterology, vol.150, issue.2, pp.380-388, 2016. ,
DOI : 10.1053/j.gastro.2015.10.050
URL : https://hal.archives-ouvertes.fr/hal-01303796
Methotrexate for maintenance of remission in ulcerative colitis, Cochrane Database of Systematic Reviews, vol.102, issue.3, p.7560, 2015. ,
DOI : 10.1002/14651858.CD007560.pub2
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial, Annals of the Rheumatic Diseases, vol.66, issue.3, pp.419-440, 2007. ,
DOI : 10.1136/ard.2006.054098
A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis Downloaded by, p.36, 2017. ,
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohn's Colitis, 2017. ,
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study ,
Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts, Digestive and Liver Disease, vol.49, issue.12, pp.1590-865830934, 2017. ,
DOI : 10.1016/j.dld.2017.06.004
Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in??inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, vol.287, issue.Pt 4, pp.863-883, 2016. ,
DOI : 10.1074/jbc.M112.363010
Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience, Scandinavian Journal of Gastroenterology, vol.8, p.1 ,
DOI : 10.1136/gutjnl-2013-306711
Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45???years: a proposed method, Alimentary Pharmacology & Therapeutics, vol.95, issue.Suppl 1, pp.1078-1086, 2009. ,
DOI : 10.1111/j.1572-0241.2002.05786.x
Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-?? agents, Autoimmunity Reviews, vol.13, issue.1, pp.15-24, 2014. ,
DOI : 10.1016/j.autrev.2013.06.005
Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab, European Journal of Gastroenterology & Hepatology, vol.28, issue.8, p.36, 2017. ,
DOI : 10.1097/MEG.0000000000000643
Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature, Alimentary Pharmacology and Therapeutics, vol.77, issue.3, pp.243-249, 2005. ,
DOI : 10.1097/00003086-199603000-00020
The Incidence and Predictors of Lupus-like Reaction in Patients with IBD Treated with Anti-TNF Therapies, Inflammatory Bowel Diseases, vol.86, issue.13, pp.2778-86, 2013. ,
DOI : 10.1097/MD.0b013e3181441a68
Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease?, Alimentary Pharmacology and Therapeutics, vol.125, issue.10, pp.1035-1078, 2004. ,
DOI : 10.1046/j.1365-2036.2003.01596.x
Prevalence and Mechanism of Nonsteroidal Anti-Inflammatory Drug???Induced Clinical Relapse in Patients With Inflammatory Bowel Disease, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.196-202, 2006. ,
DOI : 10.1016/S1542-3565(05)00980-8
The Gastrointestinal Safety and Effect on Disease Activity of Etoricoxib, a Selective Cox-2 Inhibitor in Inflammatory Bowel Diseases, The American Journal of Gastroenterology, vol.4, issue.4, pp.311-318, 2006. ,
DOI : 10.1056/NEJMoa021907
Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study, Clinical Gastroenterology and Hepatology, vol.4, issue.2, pp.203-214, 2006. ,
DOI : 10.1016/j.cgh.2005.12.002
A Long-term Cohort Study of Nonsteroidal Anti-inflammatory Drug Use and Disease Activity in Outpatients with Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.120, issue.6, pp.751-758, 2004. ,
DOI : 10.1097/00005792-197609000-00004
Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics, The Journal of Rheumatology, vol.42, issue.11, pp.2160-2165, 2015. ,
DOI : 10.3899/jrheum.140472
Antitumor Necrosis Factor-? Therapy Downloaded by, p.36, 2017. ,